Traitement des carcinoses péritonéales d'origine colo-rectale. Quoi ...

25. Shah DK, Veith J, Bernacki RJ, Balthasar JP. Evaluation of combined bevacizumab and intraperitoneal
carboplatin or paclitaxel therapy in a mouse model of ovarian cancer. Cancer Chemother Pharmacol.
2011 Feb 9.
26. Stuart OA, Stephens AD, Welch L, Sugarbaker PH. Safety monitoring of the coliseum technique for
heated intraoperative intraperitoneal chemotherapy with mitomycin C. Ann Surg Oncol. 2002
Mar;9(2):186-91.
27. Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative
approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001; 27: 239-243
28. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the
Washington Cancer Institute. Surg Oncol Clin N Am 2003; 12: 605-621, xi
29. Sugarbaker PH, Van der Speeten K, Anthony Stuart O, Chang D. Impact of surgical and clinical factors
on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis.
Eur J Surg Oncol. 2011 May 27.
30. Yan TD, Cao CQ, Munkholm-Larsen S. A pharmacological review on intraperitoneal chemotherapy for
peritoneal malignancy. World J Gastrointest Oncol. 2010 Feb 15;2(2):109-16.
31. Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH;
Peritoneal Surface Oncology Group. A novel tumor-node-metastasis (TNM) staging system of diffuse
malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer.
2011 May 1;117(9):1855-63
32. Yang XJ, Huang CK, Suo T et al. Cytoreductive and hyperthermic intraperitoneal chemotherapy
improves survival of patients with carcinomatosis from gastric cancer : final results of a phase III
randomized clinical trial. Ann Sur Onco (in press)
FCC 8 - Traitement des carcinoses péritonéales d'origine colo-rectale - quoi de neuf depuis le
rapport de l'AFC en 2008 ?